Categories: News

Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results

Conference Call Scheduled for Thursday, April 4, 2024 at 8:00 AM ET

DUBLIN, Ireland, March 28, 2024 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2023 on Thursday, April 4, 2024 at 8:00 AM ET.

Conference Call Dial-In & Webcast Information

Date: Thursday, April 4, 2024
Time: 8:00 AM ET
United States: 1-877-407-0784
International: 1-201-689-8560
Conference ID: 13745604
Call me™: https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6
Webcast Click here for webcast
   

About Trinity Biotech
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company’s website: www.trinitybiotech.com.

Contact: Trinity Biotech plc
Des Fitzgerald 
(353)-1-2769800
LifeSci Partners, LLC
Eric Ribner
(1)-646-751-4363
E-mail investorrelations@trinitybiotech.com

Staff

Recent Posts

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual…

4 mins ago

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…

4 mins ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by…

4 mins ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading…

4 mins ago

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year…

4 mins ago

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to May 3, 2024

MIAMI, March 29, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW)…

4 mins ago